ADIL Adial Pharmaceuticals, Inc.
-
Adial Pharmaceuticals, Inc. Reported Earnings
Friday, August 14, 2026 · 12:00 AM ET
Adial Pharmaceuticals, Inc. (ADIL) reported a loss of $11.25 per share on revenue of $0.00 million for the second quarter ended June 2026. .
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.
Reported Earnings
($11.25)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—